Navigation Links
The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System

Key words: serotonin • GPCR receptor binding assay LEADseeker SPA Imaging Beads

In mammals, serotonin (5-hydroxytryptamine, 5-HT) is a regulator of neural transmission which induces its biological effect by binding to serotonin receptors.

The serotonin 5-HT2C receptor is a subtype of the serotonin receptor that belongs to the rhodopsin-like seven transmembrane superfamily of G protein-coupled receptors (1). 5-HT2C receptors are widely expressed in the brain and spinal cord and are particularly enriched in the choroid plexus (2). They are reported to play a significant role in disorders such as obesity (3, 4) and hyperactivity (4). It has also been demonstrated that the 5-HT2C receptors bind a wide range of drugs used in the treatment of psychiatric disorders such as depression and schizophrenia (5, 6).

This application note describes a 384-well serotonin 5-HT2C receptor-binding assay which has been developed using the LEADseeker™ Multimodality Imaging System.

Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PEI Type RPNQ0287
A PS SPA Imaging Beads

[N6-methyl-3H]Mesulergine TRK845

Other material required
Human recombinant 5-HT2C (Euroscreen ES-315-M)
edited form, receptor membrane preparation

Mianserin hydrochloride (Sigma M2525)

Ketanserin tartrate (Sigma S006)

384-well white flat-bottom polystyrene (Corning 3705)
not-treated microplate, non-sterile

Binding buffer: 50-mM Tris pH 7.4, 0.1 %
(w/v) ascorbic acid, 10-µM pargyline.

GraphPad Prism™ software (GraphPad Software)

Human recombinant serotonin 5-HT2C, edited form, receptor membrane preparation was used in conjunction with [3H]Mesulergine ligand and WGA PEI type A PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 4-µM mianserin. The standard assay format was as follows.

1. Reagents were added in the following order: buffer or DMSO solution, unlabeled ligand (NSB wells), labeled ligand, and premixed bead and membrane. Total assay volume was 80 µl.

2. Diluted membrane and bead were premixed at room temperature immediately prior to assay addition.

3. Wells contained 10 µl of 6.08-nM [3H]Mesulergine (final concentration 0.76 nM) unless otherwise stated. Wells also contained 0.125 mg of bead and 1.25 µg of membrane, which were added together in a 20-µl volume.

4. NSB wells contained 10 µl of 32-µM mianserin (final concentration 4 µM) in addition to the above.

5. For DMSO tolerance studies, DMSO was diluted in binding buffer to give final concentrations per well as shown in the results.

6. Plates were sealed and incubated in darkness for 8 h at room temperature (20–25 ºC) unless otherwise stated.

7. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min with quasi-coincident averaging and 3 x 3 binning.

Kd determination
Satu ration binding was performed with dilutions of [3H]Mesulergine to give a range of concentrations from 30 nM to 1.18 pM in the wells. The saturation curve (Fig 1) was fitted using non-linear regression with the data analysis software package GraphPad Prism v4.0. A Kd value of 3.2 nM (95% confidence intervals 2.8 to 3.6 nM) was estimated directly from the curve.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 0.002% (v/v) to 30% (v/v) in the wells. From the results shown in Figure 2 it can be seen that the assay was tolerant to DMSO up to a final concentration of 2% (v/v).

IC50 determination
Competitive binding of 7.6-nM [3H]Mesulergine with unlabeled ketanserin and mianserin was assessed and the IC50 values calculated as shown in Figure 3. DMSO was included at an assay concentration of 2% (v/v). Final concentrations in the well for unlabeled mianserin and ketanserin were 0.3 nM to 5 µM.

The IC50 value for mianserin was determined to be 6.3 nM (95% confidence interval range 5.6 to 7.1 nM) and the Ki value was 1.8 nM (95% confidence intervals 1.6 to 2.0 nM). The IC50 value for ketanserin was 77.5 nM (95% confidence interval range 67.3 to 89.2 nM) and the Ki value was 22 nM (95% confidence intervals 19 to 25.3 nM).

Time course
A time course was performed using standard reagent concentrations as detailed in the protocol and DMSO included at an assay concentration of 2% (v/v). Readings were taken over an increased incubation time of 18 h. The assay reached equilibrium after approximately 5 h and appeared to be stable for at least a further 13 h (Fig 4).

Z analysis
Finally, a Z analysis was performed using 48 replicate values each for "total" and NSB wells, Z was determined to be 0.67 (Fig 5), which confirmed the robustness of the assay (7).

The serotonin 5-HT2C receptor-binding assay has been successfully miniaturized to 384-well format using the LEADseeker Multimodality Imaging System and is suitable for adaptation to automated screening formats. The assay is tolerant to DMSO up to a concentration of 2% (v/v), robust; achieving a Z’ value of 0.67, and has a stability window of at least 13 h.

1. Nonogaki, K., et al. Diabetes, 52, 315–320 (2003).

2. Nguyen, M. G., et al. Neuroscience, 35, 577–591 (1990).

3. Visiers, I., et al. Protein Engineering, 14 (6), 409–414 ( 2001).

4. Gibson, W. T., et al. Canadian Journal of Physiology and Pharmacology, 82 (6), 426–429 (2004).

5. Lykouras, L., et al. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 25 (3), 507–518 (2001).

6. Moreau, J. F., et al. European Journal Neuro-Psychopharmacology, 8 (3), 161–168 (1998).

7. Zhang, J., et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).

back to top


Page: All 1 2 3 4

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
4. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
7. LiquiChip Kits for bead-based cytokine and kinase assays
8. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
9. High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system
10. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
11. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B
Post Your Comments:

(Date:3/28/2017)... ... March 28, 2017 , ... LabKey ... of LabKey’s newest software solution, LabKey Biologics . Built in collaboration with ... biotech organizations, LabKey Biologics provides drug research teams tools for biological entity registration, ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), ... autoimmune disease and more through a single-cell precision engineering platform, today announced it ... developed in the laboratory of Dr. James Heath at the California Institute ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
Breaking Biology Technology:
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):